CanSino: Multiple vaccine production facilities pass Malaysia PIC/SGMP compliance inspection

LightningPacketLoss · 2026-03-06T15:38:56+00:00

CanSino's ACYW135 Meningococcal Conjugate Vaccine and 13-valent Pneumococcal Conjugate Vaccine manufacturing facilities have passed the Malaysian Drug Administration review and obtained GMP certificates, supporting drug registration in Malaysia and PIC/S countries.

LightningPacketLoss

2026-03-06 15:38:56

Abstract generation in progress

Recently, CanSino announced that its manufacturing facilities for the ACYW135 meningococcal polysaccharide conjugate vaccine and the 13-valent pneumococcal polysaccharide conjugate vaccine have passed the PIC/SGMP compliance inspection conducted by the Malaysian Drug Control Authority and have recently been awarded the GMP certificate issued by NPRA, with the certificate date being February 25, 2026.

Obtaining PIC/SGMP certification will facilitate the company’s registration and market launch of MCV4 and PCV13i vaccines in Malaysia and other PIC/S member countries.

(CanSino Announcement)

(Edited by: Yang Yan, Lin Chen)

Keywords: Healthcare

View Original

This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.

1 Likes